Covance NeoGenomics Enter Strategic Alliance for Anatomic Pathology and Specialty Laboratory Testing Services

Covance

and NeoGenomics

today announced a strategic collaboration to jointly provide anatomic pathology and specialty laboratory testing services for global clinical trials.  Through the alliance, Covance's clients will gain access to fully integrated anatomic pathology and histology (APH) services, including immunohistochemistry (IHC), fluorescence in-situ hybridization (FISH), and molecular testing.  Covance will establish a laboratory at NeoGenomics' Fort Myers, Fla. facility and, together with NeoGenomics, will provide a full range of APH, tissue-based biomarkers and other specialty testing services.  The companies will then expand joint capabilities globally at Covance's central laboratory locations in Shanghai, China; Geneva, Switzerland; and Singapore.  As part of the alliance, Covance will have access to NeoGenomics' extensive medical and scientific networks, which includes more than 500 pathologists.  NeoGenomics gains access to Covance's broad market reach, established client relationships, and extensive clinical trials experience.  The alliance will provide seamless global testing services supporting oncology and companion diagnostics strategies for